Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 
arcticnovartis

  • Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025
/by
Novartis announces commencement of tender offer to acquire Tourmaline Bio

Novartis announces commencement of tender offer to acquire Tourmaline Bio
arcticnovartis

Basel, September 29, 2025 – Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding.

/by